Zobrazeno 1 - 10
of 51
pro vyhledávání: '"F Ramis"'
Autor:
Miquel Vives-Borrás, Antoni Perelló-Bordoy, Albert Massó-van Roessel, Jaume Pons, Caterina Mas-Lladó, Vicente Peral, Maria F Ramis-Barceló, Xavier Rossello
Publikováno v:
European Heart Journal. Acute Cardiovascular Care. 10:878-889
Aims To help improving quality of care in patients with acute myocardial infarction (AMI), the European Society of Cardiology (ESC) set 20 quality indicators (QIs). There is a need to compile and summarize QI availability, feasibility, and global com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b4c6f7731e0eb88f3efbc2a68311d13
https://doi.org/10.1093/ehjacc/zuab042
https://doi.org/10.1093/ehjacc/zuab042
Autor:
A Perello-Bordoy, A Masso-Van Roessel, C Mas-Llado, M F Ramis-Barcelo, M Vives-Borras, J Pons, V Peral, X Rossello
Publikováno v:
European Heart Journal. 42
Background Quality indicators (QIs) provide a mechanism for measuring opportunities to improve cardiovascular care and outcomes. To help improving quality of care in patients with acute myocardial infarction (AMI), the European Society of Cardiology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88edabe45cb40e4f0fce72e13ea829bb
https://doi.org/10.1093/eurheartj/ehab724.1141
https://doi.org/10.1093/eurheartj/ehab724.1141
Publikováno v:
Eur Heart J Acute Cardiovasc Care
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0d20e0bd03602c355166ce3779f7402
https://pubmed.ncbi.nlm.nih.gov/33997897
https://pubmed.ncbi.nlm.nih.gov/33997897
Autor:
Marta Noris Mora, Pere Pericas, Vicente Peral Disdier, Xavier Rossello, Caterina Mas-Lladó, Rosa González Colino, José Francisco Forteza Albertí, Maria F Ramis-Barceló, Isabel Valadrón, Lucía Pasamar Márquez
Publikováno v:
High blood pressurecardiovascular prevention : the official journal of the Italian Society of Hypertension. 28(2)
Sacubitril/valsartan (S–V) has been shown to reduce clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). This benefit has been mostly attributed to an improvement in systolic function. This study aimed to evaluat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd3854766225ae2e4a5bc05be46a5aef
https://pubmed.ncbi.nlm.nih.gov/33905096
https://pubmed.ncbi.nlm.nih.gov/33905096
Autor:
M F Ramis Barcelo, M Noris Mora, C Mas Llado, A Morcuende, C I Valadron Sucasas, R Gonzalez Codino, V Peral Disdier, J.F. Forteza Alberti, L Pasamar, P Pericas Ramis, A. Rodriguez Fernandez
Publikováno v:
European Heart Journal - Cardiovascular Imaging. 21
Introduction Sacubitril/valsartan (S/V) has shown to improve mortality and reduce hospitalizations for heart failure in patients with reduced ejection fraction (HFrEF). It has been analysed its improvement in ejection fraction and left ventricle volu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b576924be1dc75f973c8de9eca70cf5
https://doi.org/10.1093/ehjci/jez319.1105
https://doi.org/10.1093/ehjci/jez319.1105
Autor:
C Mas Llado, P. Pericas, A. Rodriguez, M F Ramis Barcelo, R Gonzalez, I Valadron, J. Forteza, V Peral, L Pasamar, M Noris
Publikováno v:
European Heart Journal - Cardiovascular Imaging. 21
Introduction Patent foramen ovale (PFO) has been associated with cryptogenic stroke. Percutaneous transcatheter PFO closure has been in development for the last years. In recent studies, it has shown a reduction of recurrent ischemic stroke events. S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0f2a3ae58c39b74dabe50f55c027f8a
https://doi.org/10.1093/ehjci/jez319.432
https://doi.org/10.1093/ehjci/jez319.432
Autor:
M F Ramis Barcelo, A Martin Garcia, T Matajira Chia, M F Barreiro Perez, A I Moya Martin, C Mas Llado, Y Castillo, E Diaz Pelaez, S Merchan Gomez, E Cambronero, P L Sanchez
Publikováno v:
European Heart Journal - Cardiovascular Imaging. 20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c930fa4b8081fca59a1c48405b70d0b
https://doi.org/10.1093/ehjci/jez136.003
https://doi.org/10.1093/ehjci/jez136.003
Autor:
J Prada-Lobato, F Ramis-Riera, JJ Castellano-Herrador, MI Santos-Perez, J Rodriguez-Barbero, R Cortés-Fernandez, M Moreno-Garcia, M Madrid-Gonzalez, M Anton-Martínez
Publikováno v:
Eur J Hosp Pharm
BACKGROUND: Over the past 30 years, antiretroviral therapy (ART) for the treatment of human immunodeficiency virus (HIV) infection has experienced notable changes. Clinical research has addressed the possibility of simpler treatments. Switching from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::760293f0963fdeeada47201fe6eebe5c
https://europepmc.org/articles/PMC7535347/
https://europepmc.org/articles/PMC7535347/
Publikováno v:
Eur J Hosp Pharm
BACKGROUND: Torsade de pointes (TdP) is a ventricular tachycardia. The risk of TdP increases when the QT interval is markedly prolonged (>500 msec) or when it is combined with other risk factors such as: bradycardia, females, congenital QT prolongati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6ce0033fe68ff3e0891206685f5169c
https://doi.org/10.1136/ejhpharm-2018-eahpconf.444
https://doi.org/10.1136/ejhpharm-2018-eahpconf.444
Autor:
L Enriquez Olivar, E Queipo García, A Muñoz Martin, A Pariente, J Varela González-Aller, F Ramis, S Izquierdo Mñoz
Publikováno v:
Eur J Hosp Pharm
Background Pulmonary hypertension (PH) is a chronic disease with a high mortality rate. Therefore, choosing the right treatment at the right time is essential. Purpose To analyse which treatments were prescribed depending on the type of disease and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2a58ad18eb482ef32fc78f156910bb7
https://doi.org/10.1136/ejhpharm-2018-eahpconf.509
https://doi.org/10.1136/ejhpharm-2018-eahpconf.509